EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank43
Studio
Year-over-Year Change

Year-over-year operating income growth rate

Percentile
P43
Within normal range
vs 5Y Ago
-3x
Contraction
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025-66.90%
2024-94.30%
202324.66%
2022-80.25%
2021-48.23%
202022.09%
2019-82.16%
2018-41.44%
201714.69%
2016-439.11%